知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

138 条记录 (耗时 0.031 秒)

    Method for treating or preventing inflammatory disorders
    97.
    发明申请
    Method for treating or preventing inflammatory disorders 审中-公开
    治疗或预防炎性疾病的方法

    公开(公告)号：US20050080140A1

    公开(公告)日：2005-04-14

    申请号：US10923348

    申请日：2004-08-20

    申请人： Toshihisa Hatae ,  Chieko Yokoyama ,  Tadashi Tanabe

    发明人： Toshihisa Hatae ,  Chieko Yokoyama ,  Tadashi Tanabe

    IPC分类号： A61K45/00 ,  A61K31/00 ,  A61K31/557 ,  A61K31/5585 ,  A61K31/7088 ,  A61K38/00 ,  A61K48/00 ,  A61P29/00 ,  C12N9/90

    CPC分类号： A61K31/00 ,  A61K31/557 ,  A61K48/005 ,  C12N9/90

    摘要： According to the present invention, the gene for IL-13, an anti-inflammatory cytokine, was shown to be a target of prostacyclin (PGI2)-activated Peroxisome proliferator-activated receptor (PPAR) δ. Furthermore, the PGI2-PPARδ signaling pathway was revealed to regulate the expression of IL-13 gene in human vascular endothelial cells, and controls inflammatory responses induced by proinflammatory cytokines through the production of IL-13 in an autocrine or paracrine manner. Thus, the present invention provides a method for treating or preventing inflammatory disorders, which comprises administering a therapeutically effective amount of PPARδ agonist into a subject. Furthermore, the present invention provides a method for treating or preventing inflammatory disorders, which comprises administering a prostacyclin synthase gene or a protein encoded by the gene into a subject.

    摘要翻译： 根据本发明，IL-13的基因（抗炎细胞因子）显示为前列环素（PGI 2）活化的过氧化物酶体增生物激活受体（PPAR）三角洲的靶标。 此外，显示PGI2-PPARdelta信号通路调节人血管内皮细胞中IL-13基因的表达，并通过以自分泌或旁分泌的方式通过产生IL-13来控制由促炎细胞因子诱导的炎症反应。 因此，本发明提供了治疗或预防炎症性疾病的方法，其包括向受试者施用治疗有效量的PPARδ激动剂。 此外，本发明提供了治疗或预防炎症性疾病的方法，其包括将前列环素合酶基因或由该基因编码的蛋白质施用于受试者。

    Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
    98.
    发明授权
    Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents 有权
    环戊烷庚（烯）酸，2-杂芳基烯基衍生物作为治疗剂

    公开(公告)号：US6160129A

    公开(公告)日：2000-12-12

    申请号：US243344

    申请日：1999-02-01

    申请人： Robert M. Burk

    发明人： Robert M. Burk

    IPC分类号： C07D333/28 ,  A61K31/34 ,  A61K31/38 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5585 ,  A61P27/06 ,  C07C405/00 ,  C07D277/30 ,  C07D307/02 ,  C07D307/06 ,  C07D307/56 ,  C07D307/68 ,  C07D333/16 ,  C07D333/24 ,  C07D333/38

    CPC分类号： C07D333/28 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5585 ,  A61K31/559 ,  C07C405/00 ,  C07C405/0016 ,  C07C405/0041 ,  C07C405/0058 ,  C07D333/24 ,  C07D333/38

    摘要： The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The compounds used in accordance with the invention are represented by the following formula I: ##STR1## wherein wavy line attachments indicate either the alpha (.alpha.) or beta (.beta.) configuration; hatched segments indicate .alpha. configuration; the solid triangle is used to indicate .beta. configuration; dashed bonds represent a double bond, or a single bond; R is a substituted heteroaryl radical having at least two pendant substituents selected from the group consisting of C.sub.1 to C.sub.6 alkyl; halogen; trifluoromethyl; COR.sup.1 ; COCF.sub.3 ; SO.sub.2 NR.sup.1 ; NO.sub.2 and CN or at least one cyano group; R.sup.1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of --OR.sup.1 and --N(R.sup.1).sub.2 ; Y is .dbd.O or represents 2 hydrogen radicals and the 9, 11 or 15 lower alkyl esters thereof; provided, however, when said heteroaryl radical is a dichlorothienyl radical, the compound is not a 1-carboxylic acid or amide thereof. Certain of the compounds represented by Formula I are novel and comprise another aspect of the present invention.

    摘要翻译： 本发明涉及使用F型前列腺素衍生物作为眼部低血压。 根据本发明使用的化合物由下式I表示：其中波浪线附着物指示α（α）或β（β）构型; 阴影线段表示alpha配置; 实心三角形用于指示beta配置; 虚线键代表双键或单键; R是具有至少两个选自C 1至C 6烷基的侧基取代基的取代的杂芳基; 卤素; 三氟甲基 COR1; COCF3; SO2NR1; NO 2和CN或至少一个氰基; R 1是氢或具有至多6个碳原子的低级烷基，X选自-OR 1和-N（R 1）2; Y为= O或代表2个氢原子及其9,11或15个低级烷基酯; 但是，当所述杂芳基为二氯噻吩基时，该化合物不是1-羧酸或其酰胺。 某些由式I表示的化合物是新的并且包括本发明的另一方面。